Article
Brochure
Executive Resource
Video
Ext. Publication
Home /
Insights & Resources
Insights & Resources
Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.
- Alternative Investments
- Banking
- Blockchain & Digital Assets
- Construction
- Consumer Products
- Energy Transition
- Financial Services
- Food & Beverage
- General Business
- Government
- Health Care
- Higher Education
- Hospitality & Entertainment
- Industrial Products
- Insurance
- Life Sciences
- Not-for-Profit
- Oil & Gas
- Oilfield Services
- Real Estate
- Renewable Fuels
- Technology
- Transportation & Logistics
- Accounting Advisory
- Artificial Intelligence
- Asset Management Consulting
- Asset Tracing
- Cybersecurity
- Data Privacy
- Digital Transformation
- Energy Compliance
- ESG Strategy & Consulting
- Family Law
- Forensics & Litigation
- Government Consulting
- Health Care Valuation
- IT Advisory
- Risk Advisory
- Transaction Advisory
- Trust & Estate
- Valuation
Health Savings Account contributions and distributions work to help you save on health care costs and maximize tax benefits for future needs.
Get ahead of the curve by looking back at emerging trends in 2024 that are likely to impact health care valuation in 2025 and beyond. Download Weaver Insights now.
The shortage of key health care providers is impacting health care services. We explore factors driving demand and how this affects valuations.
J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.
KPMG has released their 2024 biopharma report detailing the challenges and opportunities for pharma companies moving forward into the new year.
Rising physician compensation and growing financial losses are putting health systems under pressure. Explore the 2024 trends and valuation insights.
The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.
The National Association of Manufacturers (NAM) conducted its Q3 Outlook Survey. Read more for a discussion and analysis of the results.
The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.
The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.
A recent U.S. complaint highlights the growing need for health care systems to ensure physician compensation aligns with fair market value to avoid compliance risks.
Ardent Health’s recent IPO highlights the company’s unique qualities, though it creates valuation comparability challenges for joint ventures and leased facilities.